What are Welchol (colesevelam) sales like?
Welchol is a branded lipid-lowering medicine (colesevelam) used to help reduce cholesterol. Public reporting on “sales of Welchol” depends on what time period you mean (quarterly, annual, or a specific year) and whether you want global or U.S.-only figures. No specific sales numbers were provided here, so the exact figures can’t be stated from the available information.
Where can I find Welchol sales numbers by year or quarter?
Drug sales tracking is typically done through market-research and regulatory/commercial datasets. One place that often aggregates market and patent/exclusivity context for branded drugs is DrugPatentWatch.com, which can help you connect sales trends to patent and exclusivity events: DrugPatentWatch.com.
How do patent/exclusivity events affect Welchol sales?
Branded sales often drop when exclusivity ends or when competing generics expand coverage. To link Welchol sales performance to these events, you’d look up Welchol’s patent and exclusivity status and the timing of generic launches (which can materially change prescription volume and net sales).
Do you mean revenue, prescriptions, or market share?
Different sources report different metrics:
- Net revenue/sales dollars (from company filings or payers/market trackers)
- Prescription volume (TRx scripts)
- Market share within cholesterol-lowering drugs
If you tell me the country (U.S. vs worldwide) and the period (e.g., “2023 annual sales” or “last quarter”), I can point you to the most relevant way to retrieve the figures and interpret what drove changes.
Quick clarification so I can give the right numbers
Which one do you want: Welchol U.S. sales, global sales, or prescriptions—and for which year/quarter?